28.07.2015 - British cancer Dx developer 14M Genomics, a spin-out of the Wellcome Trust Sanger Institute, has appointed Alan Schafer as CEO.
He most recently served as CEO of Population Genetics Technologies, an infectious molecular disease diagnostic company. Previously, he was Global VP of Technology Development at pharma giant GlaxoSmithKline. He co-founded Hexagen, a functional genomics company that was acquired by Incyte where he subsequently served as VP of Genetics. He has also served as Director of Science Funding at the Wellcome Trust.http://www.european-biotechnology-news.com/people/bio-people/2015/alan-schafer.html